Journal of Clinical Oncology
Articles in this Issue
Molecular pathways of immune checkpoint inhibitor–induced hepatitis.
2573 Background: Immune checkpoint inhibitor (ICI) related hepatitis is a clinically significant immune-related adverse ev...
Accumulation of cholesterol, cortisol, and glutathione in mitochondria as a marker of metabolic adaptation in serous and clear cell endometrial carcinoma.
5617 Background: Aggressive endometrial carcinoma subtypes, such as serous (USC) and clear cell (CCC) carcinomas, are char...
Experimental modeling of soft tissue sarcomas with invasion into bone structures.
e23541 Background: This study aimed to establish and characterize PDX models of STS with bone invasion, evaluating their g...
Hospital volume, travel burden, and survival disparities in stage IV melanoma: A U.S. national cohort.
e21597 Background: Advances in immunotherapy and selective surgical resection have improved outcomes for stage IV melanoma...
Development and evaluation of a dark kinase–based transcriptional score in acute myeloid leukemia.
e22641 Background: Dark kinases regulate cellular stress responses and transcriptional plasticity but remain largely unexp...
Outcomes of patients with glioblastoma multiforme (GBM) with lymphopenia.
e14053 Background: Lymphopenia has been associated with adverse survival outcomes in multiple solid tumors; however, its p...
Comparison of talquetamab vs teclistamab in relapsed refractory multiple myeloma.
e19502 Background: Talquetamab (TQ) and Teclistamab (TC) are both FDA approved bispecific antibodies used in the treatment...
Fluorescence-guided surgery with 5-aminolevulinic acid (5-ALA) in ovarian, fallopian tube, and primary peritoneal cancers: Efficacy and safety results from the GINGA study.
5582 Background: Administration of 5-aminolevulinic acid (5-ALA) results in tumor-selective accumulation of protoporphyrin...
Prognostic impact of TP53 co-mutation and interleukin gene expression in EGFR-mutant advanced lung cancer.
e20674 Background: EGFR-mutant non–small cell lung cancer (NSCLC) demonstrates marked biological heterogeneity despite tar...
Phase I trial to evaluate the safety and tolerability of fb-PMT in patients with recurrent glioblastoma.
2070 Background: Proliferative, pro-angiogenesis, and pro-inflammatory actions mediated by L-thyroxine in glioblastoma (GB...
Analysis of healthcare professional management of CDK4/6 inhibitor adverse events and variance with expert recommendations.
e13103 Background: CDK4/6 inhibitors (CDK4/6is) are a mainstay of treatment for hormone receptor–positive breast cancer bu...
Outcomes in patients with metastatic renal cell carcinoma (mRCC) who complete 18 months of first-line IO-TKI therapy: A conditional survival analysis from the IMDC.
e16528 Background: Immuno-oncology and tyrosine kinase inhibitor (IO-TKI) combinations are standard first-line (1L) treatm...
Multimodal modeling of CCI, CCI, FaceAge, thymic health, and OS among older adults with early-stage NSCLC undergoing SBRT.
e20006 Background: Lung cancer disproportionately affects older adults, who have diverse care needs and inferior clinical...
TRUCE-11: An open-label, single-arm, multicenter phase II study of tislelizumab combined with nab-paclitaxel for muscle-invasive urothelial bladder carcinoma.
4618 Background: Neoadjuvant tislelizumab plus nab-paclitaxel may enhance pathologic response in muscle-invasive bladder c...
Oral estrogen receptor (ER) degraders compared to standard endocrine therapy (ET) in ER-positive, human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer (MBC): A systematic review and meta-analysis.
1087 Background: Treatment with ER-positive HER2-negative (ER+HER2-) MBC has evolved during the past decade. Several novel...
Impact of pleural effusion on mortality and hospitalization in stage IV <i>EGFR</i> -mutated NSCLC treated with osimertinib: A real-world analysis.
e20646 Background: Pleural effusion (PE) is common in advanced non–small cell lung cancer (NSCLC) and may reflect aggressi...
Genetic associations with chemotherapy-induced nausea and vomiting: A genome-wide association study.
12050 Background: Nausea and vomiting affect up to 80% of patients treated with chemotherapy, and the costs of healthcare...
The phase I therapeutic landscape in pancreatic ductal adenocarcinoma: Molecular profiling and emerging strategies.
e15114 Background: Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with limited treatment options. Phase I...
Clinical validation of circulating tumor cell synaptophysin and androgen receptor expression in metastatic prostate cancer phenotypes.
5041 Background: Chronic exposure to androgen receptor (AR) targeted therapies can drive lineage plasticity, promoting the...
Leptomeningeal disease in ALK-positive NSCLC: Survival impact of third-generation ALK inhibitors.
8644 Background: As survival outcomes for patients with ALK-positive non-small cell lung cancer (NSCLC) continue to improv...
Genome-wide association study of tyrosine kinase inhibitor–induced hepatotoxicity in All of Us.
e15130 Background: Tyrosine kinase inhibitors (TKIs) are widely used as standard therapies for a variety of malignancies;...
Genomic correlates of leptomeningeal disease after brain metastasis resection.
2032 Background: Leptomeningeal disease (LMD) remains a frequent and devastating pattern of failure following surgical res...
Comparative yield of three models to evaluate germline genetic risk in patients (pts) with pancreatic cancer (PCA): A single-institution study.
e22647 Background: ~10% of PCA patients (pts) have a germline pathogenic variant (gPV) in a hereditary CA risk gene. After...
Online biographies of gynecologic oncologists: Analysis of linguistic differences based on gender, graduation year, and region.
e17535 Background: Selecting a physician is a universal act for patients. This process has been reshaped by the digital tr...
Large language models as decision support in the absence of genomic profiling: A simulated prospective study on early-stage breast cancer.
e12553 Background: Genomic profiling guides adjuvant chemo in early-stage BC but remains inaccessible in resource-constrai...